Clay Thorp - 10 Feb 2021 Form 4/A - Amendment Insider Report for Clearside Biomedical, Inc. (CLSD)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact for Clay Thorp
Issuer symbol
CLSD
Transactions as of
10 Feb 2021
Net transactions value
-$145,627
Form type
4/A - Amendment
Filing time
19 Dec 2022, 18:40:21 UTC
Date Of Original Report
10 Feb 2021
Next filing
04 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLSD Common Stock Sale $145,627 -32,873 -0.66% $4.43 4,951,547 10 Feb 2021 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on March 16, 2020.
F2 Consists of (i) 447 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 21,095 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 1,916 shares sold by Hatteras Venture Affiliates III, LP ("HVA III") and (iv) 9,415 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").
F3 This transaction was executed in multiple trades at prices ranging from $4.40 to $4.50, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F4 The original Form 4 inadvertently misstated the total number of shares. This reflect the accurate number of shares beneficially owned.